Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques
Laura Evgin(University of British Columbia), J. Andrea McCart(Toronto General Hospital), Harold Atkins(University of Ottawa), Gregory L. Stahl(Brigham and Women's Hospital), Caroline J. Breitbach(University of Ottawa), John C. Bell(Ottawa Hospital), Rebecca C. Auer(Ottawa Hospital), Christiano Tanese de Souza(Ottawa Hospital), Chantal G. Lemay(University of Ottawa), Joshua M. Thurman(University of Colorado Denver), Sergio A. Acuña(University of Alabama), John D. Lambris(University of Pennsylvania), David Hanwell(University Health Network), Roberto Lopez(University Health Network), Alyssa Goldstein(University Health Network), Carolina S. Ilkow(Ottawa Hospital), Sandra Lafrance(University Health Network), C. Scott Findlay(University of Ottawa), David H. Kirn(Alameda Applied Sciences Corporation (United States)), Monique Marguerie(Ottawa Hospital), Kelley A. Parato, Theresa Falls(Ottawa Hospital)
Cited by 80
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense
|Immunological Reviews|2016|510
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503